Document Detail

Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators.
MedLine Citation:
PMID:  7746398     Owner:  NLM     Status:  MEDLINE    
Studies in laboratory animals indicate that certain centrally acting drugs (eg, the antihypertensives clonidine and prazosin, neuroleptics and other dopamine receptor antagonists, benzodiazepines, and the anticonvulsants phenytoin and phenobarbital) impair behavioral recovery after focal brain injury. Even single doses may have long-term harmful effects. To determine whether these medications have a similar negative impact in humans, we analyzed the recoveries of control patients who were enrolled in the Sygen in Acute Stroke Study, a multicenter study of the effects of GM1 ganglioside after ischemic stroke. Motor impairments were measured by the motor subscores of the Toronto Stroke Scale at baseline and 7, 14, 21, 28, 56, and 84 days after stroke. Using these data, we compared motor recovery between patients with initial motor deficits who received at least one of the drugs that interfere with recovery in laboratory studies ("detrimental" drug group, n = 37) and patients who did not receive these drugs ("neutral" drug group, n = 59). The groups were well balanced with regard to the frequency of comorbid conditions and other prognostic factors. For upper-extremity motor function, repeated-measures ANOVA showed a significant interaction between drug group and time after stroke [F(6,528) = 2.38; p = 0.03], with a significant (p < 0.001) difference between the groups beginning 7 days after the stroke. A similar trend was present for the lower extremity, but the overall difference between the groups was not significant [ANOVA F(6,498) = 1.22; p = 0.29]. Drug group did influence the degree of independence in activities of daily living as measured with the Barthel Index.(ABSTRACT TRUNCATED AT 250 WORDS)
L B Goldstein
Related Documents :
17446028 - Imaging treatment effects in alzheimer's disease.
21639118 - Application of cyp102a1 m11h as tool for the generation of protein adducts of reactive ...
18203948 - Progress in brain penetration evaluation in drug discovery and development.
6531078 - Intracerebroventricular vs. subcutaneous drug administration: apples and oranges?
8334198 - Fatal outcome of a patient with severe aplastic anemia after treatment with metenolone ...
11532318 - Emulsions containing partially water-miscible solvents for the preparation of drug nano...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Neurology     Volume:  45     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-06-15     Completed Date:  1995-06-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  865-71     Citation Subset:  AIM; IM    
Department of Medicine, Duke University, Durham, NC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Cerebrovascular Disorders / drug therapy*,  physiopathology*
Double-Blind Method
Drug Therapy / adverse effects*
Middle Aged
Movement / drug effects*
Muscles / drug effects,  physiopathology
Time Factors
Comment In:
Neurology. 1996 Apr;46(4):1187-8   [PMID:  8780129 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early anticoagulation after large cerebral embolic infarction: a safety study.
Next Document:  Sudden death from aneurysmal subarachnoid hemorrhage.